Teza Capital Management LLC Sells 10,705 Shares of Repligen Co. (NASDAQ:RGEN)

Teza Capital Management LLC cut its holdings in Repligen Co. (NASDAQ:RGEN) by 78.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,921 shares of the biotechnology company’s stock after selling 10,705 shares during the period. Teza Capital Management LLC’s holdings in Repligen were worth $420,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD increased its position in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. increased its position in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after buying an additional 594,189 shares in the last quarter. Groupama Asset Managment increased its position in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after buying an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in Repligen in the 4th quarter valued at about $53,428,000. Finally, Raymond James Financial Inc. bought a new stake in Repligen in the 4th quarter valued at about $52,492,000. 97.64% of the stock is owned by institutional investors.

Insider Transactions at Repligen

In other news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $127.59 on Wednesday. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The stock’s 50 day moving average price is $132.06 and its 200-day moving average price is $144.99. The company has a market capitalization of $7.17 billion, a PE ratio of -250.18, a PEG ratio of 4.54 and a beta of 1.21. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the previous year, the business earned $0.28 EPS. The company’s revenue was up 10.4% compared to the same quarter last year. On average, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on RGEN shares. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, May 8th. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. JPMorgan Chase & Co. cut their price target on Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.